Service de Dermato-Cancérologie, CHU Hôtel-Dieu, Nantes, France.
Laboratoire de radio-immunologie, CHU Hôtel Dieu, Nantes, France.
J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1347-53. doi: 10.1111/jdv.12857. Epub 2014 Dec 16.
Verneuil's disease is a chronic inflammatory skin disease of the follicles in apocrine glands rich area of the skin (axillary, inguinal, anogenital) and is associated with a deficient skin innate immunity. It is characterized by the occurrence of nodules, abscesses, fistulas, scars. Recently, vitamin D has been shown to stimulate skin innate immunity.
The primary objective of the study was to assess whether Verneuil's disease was associated with vitamin D deficiency. The secondary objective was to determine whether vitamin D supplementation could improve inflammatory lesions.
First, 25(OH) vitamin D3 serum levels in patients with Verneuil's disease followed at Nantes University Hospital were compared to those of healthy donors from the French Blood Bank. Then, a pilot study was conducted in 14 patients supplemented with vitamin D according to their vitamin D level at baseline at months 3 and 6. The endpoints at 6 months were decreased by at least 20% in the number of nodules and in the frequency of flare-ups.
Twenty-two patients (100%) had vitamin D deficiency (level <30 ng/mL) of whom 36% were severely deficient (level <10 ng/mL), having correlation with the disease severity (P = 0.03268) vs. 20 controls with vitamin D deficiency (91%) of whom 14% were severely deficient. In 14 patients, the supplementation significantly decreased the number of nodules at 6 months (P = 0.01133), and the endpoints were achieved in 79% of these patients. A correlation between the therapeutic success and the importance of the increase in vitamin D level after supplementation was observed (P = 0.01099).
Our study shows that Verneuil's disease is associated with a major vitamin D deficiency, correlated with the disease severity. It suggests that vitamin D could significantly improve the inflammatory nodules, probably by stimulating the skin innate immunity. A larger randomized study is needed to confirm these findings.
伏诺依氏病是一种慢性炎症性皮肤疾病,发生于富含顶泌汗腺的皮肤区域(腋窝、腹股沟、肛门生殖器),与皮肤固有免疫缺陷有关。其特征为结节、脓肿、瘘管和疤痕的发生。最近,维生素 D 已被证明可刺激皮肤固有免疫。
本研究的主要目的是评估伏诺依氏病是否与维生素 D 缺乏有关。次要目的是确定维生素 D 补充是否可以改善炎症病变。
首先,比较了在南特大学医院就诊的伏诺依氏病患者的 25(OH)维生素 D3 血清水平与法国血液银行健康供体的水平。然后,对 14 名患者进行了一项试点研究,根据基线时的维生素 D 水平,在第 3 个月和第 6 个月进行了维生素 D 补充。6 个月时的终点是结节数量减少至少 20%,且发作频率降低。
22 名患者(100%)存在维生素 D 缺乏(水平 <30ng/mL),其中 36%为严重缺乏(水平 <10ng/mL),与疾病严重程度相关(P=0.03268),而 20 名对照者中有 14%为严重缺乏(91%)。在 14 名患者中,补充治疗在 6 个月时显著减少了结节数量(P=0.01133),其中 79%的患者达到了终点。观察到治疗成功率与补充后维生素 D 水平升高的重要性之间存在相关性(P=0.01099)。
本研究表明,伏诺依氏病与严重的维生素 D 缺乏有关,与疾病严重程度相关。提示维生素 D 可显著改善炎症性结节,可能通过刺激皮肤固有免疫来实现。需要更大规模的随机研究来证实这些发现。